ISRCTN41456162 https://doi.org/10.1186/ISRCTN41456162

Effect of an angiotensin receptor antagonist on cerebral blood flow, cerebral perfusion pressure, and systemic and peripheral haemodynamics in patients with acute stroke

Submission date
07/07/2008

Recruitment status
No longer recruiting

Registration date
29/07/2008

Overall study status
Completed

Last Edited
04/01/2019

Condition category
Circulatory System

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Gillian Sare

Contact details
Division of Stroke Medicine
Clinical Sciences Building
City Hospital
Nottingham
United Kingdom
NG5 1PB
+44 (0)115 8231769
abc@123.com

Additional identifiers

Clinical Trials Information System (CTIS)
2006-005082-19

Protocol serial number
1.1

Study information

Scientific Title
Effect of an angiotensin receptor antagonist on cerebral blood flow, cerebral perfusion pressure, and systemic and peripheral haemodynamics in patients with acute stroke

Acronym
TAST

Study objectives
The hypothesis is that it is possible to lower blood pressure in hypertensive patients with acute stroke using telmisartan (an angiotensin receptor antangonist) without reducing cerebral blood flow.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Ethics approval received from the UK National Research Ethics Service - committee LNR1 on the 11th December 2006 (ref: 06/Q2501/228)

Study design
Single centre, interventional, randomised, double blind placebo controlled trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Hypertension in acute stroke

Interventions
Telmisartan 80 mg once a day or matched placebo. The patients are in the trial for 90 days, and receive treatment for the whole period.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Telmisartan

Primary outcome(s)
Quantitative cerebral blood flow (xenon computed tomography [CT] figure) before and 1.5 hours after first treatment.

Key secondary outcome(s))
1. Middle cerebral artery blood flow velocity (MCABFV) and pulsatility index (transcranial doppler [TCD])
2. Central blood pressure
3. Augmentation index (AI [applanation tonometry at carotid and radial arteries on ipsilateral side, SphygmoCor])
4. Peripheral blood pressure
5. Heart rate (Omron)

Measured at baseline, and 4.5 hours after first dose, day 4, 7 and 90 treatment.

Completion date
30/11/2009

Eligibility

Key inclusion criteria
1. Patients must have suffered ischaemic or haemorrhagic stroke
2. Patients must be 18 years of age or over, either sex
3. Onset date of stroke is less than 5 days
4. Systolic blood pressure (BP) greater than 140 mmHg

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 years

Sex
All

Key exclusion criteria
1. Less than 18 years of age
2. Normotension or hypotension (systolic BP less than 140 mmHg)
3. Onset date more than 5 days
4. Coma (Scandinavian Stroke Scale [SSS] less than 4)
5. Patients who are of childbearing potential, pregnant or breastfeeding

Date of first enrolment
01/07/2007

Date of final enrolment
30/11/2009

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Division of Stroke Medicine
Nottingham
United Kingdom
NG5 1PB

Sponsor information

Organisation
University of Nottingham (UK)

ROR
https://ror.org/01ee9ar58

Funder(s)

Funder type
Charity

Funder Name
British Heart Foundation (BHF) (UK) (ref: PG/05/137/19999)

Alternative Name(s)
the_bhf, The British Heart Foundation, BHF

Funding Body Type
Private sector organisation

Funding Body Subtype
Trusts, charities, foundations (both public and private)

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	05/06/2013		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes